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A COMPARATIVE STUDY OF SYNBIOTIC  AS AN ADD ON THERAPY 
TO STANDARD TREATMENT  IN PATIENTS WITH AGGRESSIVE 
PERIODONTITIS 
ABSTRACT 
AIM: 
 
To evaluate the efficacy and safety of Synbiotic as an add on therapy to Standard  
treatment inthe management of patients with Aggressive Periodontitis  compared to 
Standardtreatment alone. 
 
METHODOLOGY 
 
This was arandomized, prospective, placebo controlledstudy.60 patients with Aggressive 
Periodontitis wererandomized and blinded into two groups of 30 each. Control group 
received Scaling and Root planing [SRP] +Cap.Doxycycline 100mg twice daily for one 
week +Placebo one lozengetwice daily for 8 weeks  andStudy group receivedScaling and 
Root planing [SRP] +Cap.Doxycycline 100mg twice daily for one week +Synbioticone 
lozenge twice daily for 8 weeks.The clinical parameters were recorded at baseline, 4,8 and 
12 weeks.Oral hygiene index[OHI],Gingival bleeding index[GBI],Probing depth[PD] and 
Clinical attachment loss[CAL] were assessedat baseline and at the end of the study. 
 RESULTS 
 
106patients were screened out of which 60 patients were included in the study.All patients 
completed the study and were included in analysis.On comparing the groups at the end 
of12weeks there was a statistically significant reduction (P<0.01) inOHI,GBI,PD & CALin 
Study group. No significant difference in the incidence of adverse events noted between 
the two groups. 
 
CONCLUSION 
 
Synbioticalong with standard therapy is highly efficacious in reducingOHI,GBI,PD & 
CALinpatients with Aggressive Periodontitis. 
 
KEY WORDS 
 
Synbiotic, Aggressive Periodontitis,Probing Depth,Clinical Attachment Loss. 
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INTRODUCTION 
              Periodontitis is one of the most common oral diseases with various 
incidence rates in different population. It is a chronic inflammatory disease of 
infectious origin leading to destruction of tooth-supporting tissues and is the major 
cause of tooth loss in young individuals1. 
             The features of periodontitis include inflammatory changes in the gingiva, 
formation of pockets in the periodontal region, loss of connective tissues and 
alveolar bone around the affected tooth. If not treated properly loosening of tooth 
occurs and subsequently can lead on to loss of tooth2.  
             Periodontitis can be classified into Aggressive periodontitis which is 
characterized by a rapid destruction of periodontal attachment and 
Chronicperiodontitis which is slowly progressive leading to gradual loss of 
attachment of supporting tissues. 
            Aggressive form of the disease commonly affects systemically healthy 
individuals less than 30 years old. It can be subdivided into Localized and 
Generalized aggressive periodontitis. The Localized form does not involvemore 
than two teeth. First molars and incisors are commonly affected. In Generalized 
form, at least three permanent teeth are involved other than first molars and 
incisors3. 
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            The etiology of Aggressive disease is very complex. Pathogenic bacteria are 
the primary etiologic agents in the pathogenesis of periodontitis. Although a number 
of bacteria are considered as the major etiologic agents of aggressive periodontitis, 
Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis are the 
most common pathogens that get attached to the surfaces of the tooth eliciting an 
immuneresponse from the host. Apart from this, contributing factors include 
genetics, environment and host factors4. 
             In theadolescent population, aggressive periodontitis has a prevalence of 
below 1%and sometimes it may affect older patients. It affects both males and 
females.Some studies have suggested a predilection for female patients, particularly 
in the youngest age groups. The risk in black population is higher when compared 
to white population5,6. 
             The main symptoms are pain and loosening of teeth in the affected areas. 
Gum bleeding may occur spontaneously or upon stimulation. Aggressive disease is 
diagnosed by inspection of the soft gum tissues around the teeth with a probe 
(clinical examination), by evaluation of the patient’s x-ray films (radiographic 
examination) to determine the amount of bone loss around the teeth and by 
detecting the presence of pathogenic bacteria in the saliva (microbiological 
examination)7.  
             The most common and conventional treatment for Aggressive periodontitis 
is Scaling and Root planingunder the coverage of systemic antibiotics. Among all 
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the antibiotics, the most efficacious in treating aggressive periodontitis is 
doxycycline.  But, the overuse and misuse of antibiotics over time has led to the 
emergence of drug resistant microorganisms. 
             The use of antibiotics may also disturb the indigenous microflora of the 
body which includes Lactobacilli in the oral cavity. Hence, it is better to avoid the 
use of antibiotics that are highly active against Lactobacilli. Recently the trend has 
shifted towards the usage of probiotics and prebiotics.8 
             Probiotics are live micro-organisms with beneficial effects whereas 
Prebiotics are non digestible food components that stimulate probiotics. Synbiotic is 
a mixture of pre & probiotics and commonly includes Streptococcus faecalis, 
Clostridium butyricum, Bacillus mesentricus and Lactobacillus sporogenes. Here, 
the bacteria which are beneficial to health are stimulated to grow. They also act 
against those bacteria that are harmful and modify the immunity of oral mucosa.9 
            In the care of oral cavity, the use of probiotics is a breakthrough. Though 
there are many studies showing the benefits of probiotics in oral diseases, data 
among South Indian population are limited. Therefore this study has been 
undertaken to evaluate safety and efficacy of synbiotic in patients with aggressive 
periodontitis in our population.  
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REVIEW OF LITERATURE   
 
PERIODONTITIS 
                  Periodontal diseases comprise two inflammatory conditions-  
1) Gingivitis and 2)Periodontitis. Both conditions affect tissues encircling and 
enclosing the tooth. The process is initiated with inflammation of the gum 
(gingivitis) and if it is not treated, slowly the inflammatory process advances to 
involve periodontal fibers and alveolar bone surrounding the tooth (periodontitis).10 
                  Periodontitis is defined as "an inflammatory disease of the supporting 
tissues of the teeth caused by specific microorganisms or groups of specific 
microorganisms, resulting in progressive destruction of the periodontal ligament 
and alveolar bone with increased probing depth formation and clinical attachment 
loss".11 
CLASSIFICATION  OF  PERIODONTITIS :11 
 
1. Chronic Periodontitis 
2. Aggressive Periodontitis 
3. Periodontitis as a Manifestation of Systemic Diseases 
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CHRONIC PERIODONTITIS: 
 Age of onset : adults  > 35 years old 
 Rate of disease progression : slow to moderate 
 Presence of abundant plaque and calculus 
 Different bacterial pattern 
 Sub classified into localized (<30% of sites involved) and generalized (>30% 
of sites involved) forms. 
 
AGGRESSIVE PERIODONTITIS: 
When compared to chronic periodontitis aggressive periodontitis has the following 
main features 
 Excepting for the disease process in periodontal region , they are otherwise 
healthy 
 The loss of attachment of supporting connective tissues and destruction of bone 
are rapid. 
 Positive family history 
 Defect in the Neutrophils (PMNs) leading to failure in its functions of   
chemotaxis and phagocytosis. 
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The other presentations include 
 The amount of microbial deposits does not coincide with the severity of the  
disease 
 The organisms implicated  areAggregatibacteractinomycetemcomitans and in 
some cases Porphyromonas gingivalis  
 Levels  of prostaglandin E2 (PGE2) and interleukin 1β (IL) are increased 
 Phagocytic abnormalities 
According to the 1999 Consensus Report published by the American Academy of 
Periodontology (AAP), aggressive periodontitis was sub classified into localized 
and generalized forms.  
Localized aggressive periodontitis (LAP): 
 The onset is commonly at the time of puberty 
  First molar/incisor are mostly involved 
 Strong antibody response to the offending agent  
 Inflammation of gingiva, edema, bleeding, pocketing 
Generalized aggressive periodontitis (GAP): 
 Less  than 30 years age group  are commonly involved 
 Poor  antibody response to  agents causing infection 
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 The destruction of periodontal tissues are more pronounced and are episodic 
in nature 
 It affects at least three permanent teeth other than first molars and incisors. 
 When compared to LAP the  destruction of bone is larger and is  more rapid 
 Bleeding, deep pocketing , periodontal abscess - present  
PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES: 
1. Hematologic disorders 
 Acquired neutropenia 
 Leukemias and Others  
2. Genetic disorders 
 Familial and cyclic neutropenia 
 Down syndrome 
 Leukocyte adhesion deficiency syndromes 
 Glycogen storage disease 
 Infantile genetic agranulocytosis and Others 
3. Not otherwise specified 
 
EPIDEMIOLOGY:12,13 
              The prevalence of localized aggressive periodontitis is estimated to be 
below 1% in geographically diverse adolescent populations. It affects both the 
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sexes. Mostly the incidence is between puberty and twenty years of age.  Larger 
incidence particularly in young female patient have been shown in some studies. 
                 In the US national survey of adolescents aged 14 to 17, 0.53% had 
localized formand 0.13% had generalized form of the disease. In blacks, male 
teenagers had 2.9 times higher incidence than female adolescents, whereasin whites, 
females were at greater risk for the disease than males.  
                In a study of untreated periodontal disease conducted in Sri Lanka by Loe 
et al, 8% of the population had generalized aggressive periodontitis. In addition, 
blacks were at greater risk than whites for all forms of aggressive periodontitis. 
 
ETIOLOGY AND PATHOGENESIS:11 
               Aggressive periodontitis has the feature of loosening of teeth and 
destruction of supporting tissues in the periodontal region at an early age. The 
aggressive nature is attributed to the expression of highly virulent causative agents 
or high levels of patient's susceptibility or both. 
 
Microbiologic Factors: 
              The etiology of periodontitis is very complex including the oral biofilm 
which triggers the immuno-inflammatory response in a susceptible host. This 
destroys the periodontal region. Pathogenic bacteria are the primary etiology agents 
in the pathogenesis of periodontitis. There are about 700 different organisms in the 
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oral flora. Of these species, only some micro-organisms have been specifically 
associated with periodontal diseases.  
             The majority of periodontal pathogens are Gram-negative and strict 
anaerobe. Among the most important species, Aggregatibacter 
actinomycetemcomitans is the main cause of Aggressive form of the disease. Other 
bacteria are Porphyromonasgingivalis, Tannerella forsythia, Treponemadenticola, 
Fusobacteriumnucleatum, Prevotellaintermedia, Prevotellanigrescens, 
Campylobacter rectus, Eikenellacorrodens and Parvimonasmicra.Eventhough all 
these bacterial species have been associated with progression of periodontal 
destruction,   A. actinomycetemcomitans is identified  as primary organism causing 
this  disease. This is based on the facts put forward by Tonetti and Mombelli which 
includes: 
 A.actinomycetemcomitans is isolated in around 90% of  the lesions of 
aggressive periodontitis  
 Most of the patients who show clinical evidence of this disease have 
their serum showing higher levels of antibody titre to this organism. 
Studies have shown that there is a decrease in the bacterial load when 
the patient is successfully responding to treatment. 
 A lot of virulence factors contributing to the disease have been 
attributed to this organism. 
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                     In some studies, no significant association was found between the 
presence of aggressive disease and A. actinomycetemcomitans. In other 
studies,increased levels of P. gingivalis, P. intermedia, Fusobacteriumnucleatum, C. 
rectus and Treponemadenticolawere found in patients with either localized or 
generalized form of the disease. 
                     In addition, A.actinomycetemcomitans can be detected in healthy 
personswho are not suffering from any periodontal disease. This suggests that this 
organism is a part of the normal flora. 
 
Immunologic Factors: 
                  Studies were conducted to establish   a link between immune regulators 
like the human leukocyte antigens (HLA) and aggressive periodontitis. Though the 
results were inconsistent, HLA-A9 and B15  have shown strong association with 
this disease. 
                 Several researchers have shown that polymorphonuclear leukocytes 
(PMNs) are defective in patients with aggressive form. This can ultimately lead to 
failure of chemotaxis and phagocytosis.  
               In recent studies, a hyperresponsiveness of monocytes from localized 
aggressive periodontitis patients linked with their production of PGE 2 in response 
to lipopolysaccharide (LPS) have also been demonstrated.  This hyperresponsive 
phenotype could lead to increased connective tissue or bone loss due to these 
excessive factors leading to destruction. 
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               In addition, poorly functional inherited forms of monocyte FcyR II, the 
receptor for human IgG2 antibodies are found in increased levels in patients having  
localized aggressive periodontitis. The defective functions of PMN and monocyte 
may either be due to infection or may be of genetic origin.  
              Autoimmunity may also play a role in generalized aggressive periodontitis 
according to Anusaksathien and Dolby who found host antibodies to collagen, DNA 
and immunoglobulin G (IgG). Possible immune mechanisms include an increase in 
the expression of type II major histocompatibility complex (MHC) molecules, HLA 
DR43, altered helper or suppressor T-cell function, polyclonal activation of B cells 
by microbial plaque and genetic predisposition. 
 
Genetic Factors: 
             Evidence suggests inherited immunological defects may be associated with 
this disease. For example, Van Dyke et al have shown that the abnormalities in 
neutrophils occurring in localized aggressive periodontitis is associated with 
familial clustering. This clustering suggests that the defects may be inherited. 
              The main pathogen A. actinomycetemcomitans is genetically 
influenced.The antibody response against this pathogen is genetically controlled. 
Tonetti and Mombelli have summarized that the genes responsible for 
pathogenecity may be different in different ethnic groups explaining true genetic 
heterogeneity. 
 
21 
 
 
Environmental Factors: 
             Smoking is a risk factor for this disease. The severity of the disease 
particularly in young individuals depends on the amount and duration  for which the 
individual smokes.Patients  who smoke have more severe  generalized aggressive 
periodontitis than non smokers who are suffering from the  same disease. However, 
this is not the same in case of localized aggressive periodontitis. 
 
Current concepts: 
o The cause for aggressive periodontitis is multifactorial. Numerous factors 
interact in a complex manner resulting in the disease process. 
o Inheritance of Aggressive periodontitis susceptibility is probably not 
sufficient. 
o The environment also plays a role in the disease process. Exposure and the  
virulence of the organism plays a part. 
o Host inability to effectively deal with the bacterial aggression and to avoid 
inflammatory tissue damage results in the initiation of the disease process.  
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 It represents the interactions between environmental (e.g. cigarette smoking) and 
genetically controlled (e.g. IgG2 response to A.actinomycetemcomitans.) modifying 
factors leading to development of Localized (LAP) and Generalized Aggressive 
Periodontitis (GAP). 
 
Clinical features: 
 Clinically, the localized form does not involve more than two teeth and  first 
molars/incisors are commonly affected, whereasin generalized form, at least 
three permanent teeth are involved other than first molars and incisors. 
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 Presence of periodontal pockets and the characteristic absence of 
inflammation are the main features of localized aggressive periodontitis. 
 In most cases the plaques present on the diseased teeth is lesser when 
compared to the amount of destruction of periodontal tissues. 
 A biofilm is formed over the diseased teeth by the plaque and this can in a 
rare instance lead to formation of calculus. 
 When compared to chronic periodontitis , the progression of the disease is 
rapid and is about  three to four times faster.14 
 
Other clinical features:15 
 Disto labial migration of the maxillary incisors 
 Increasing teeth mobility 
 The supporting structures get irritated during the act of mastication and this 
can lead on to a deep pain which is dull and radiating. 
 Increased sensitivity to the stimulus of heat and tactile sensation on the 
denuded root surfaces can be present. 
 
Radiographic features: 
 Localized form of the disease shows characteristic arc-shaped 
radiolucent mirror image in the first molars starting from the distal 
aspect of second premolars to the mesial aspect of the second molar. 
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 The generalized form of the disease shows bony destruction in a 
generalized manner on radiographic images. The severity determines 
the amount of destruction. It may range from mild destruction of 
crestal bone to greater destruction of alveolar bone. Bony defects may 
be horizontal or vertical or both16. 
 
 
Diagnosis: 
Early diagnosis plays a huge role in preventing the loss of attachment of 
periodontal soft tissues and loss of bone. The American Academy of periodontology 
has set some criteria for diagnosing. This includes history, clinical features and 
radiographic features with microbial examination if required. 
History of loss of tooth at an earlier age in the family may be positive. In 
contrast to chronic periodontitis the amount of plaque and the amount of organisms 
deposited may not be consistent with the amount of destruction. Radiographs are 
taken in a serial manner and compared to establish the rate of destruction, thereby 
aiding in diagnosis. 
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Differential Diagnosis: 
 Rapid nature of progression of the disease, age of onset, gingival 
microbiology, immune system alterations and a positive family history helps 
in differentiating aggressive forms from chronic forms of the disease. 
 Systemic forms may be of hematologic or genetic origin can be 
differentiated by careful systemic examination, hematological and 
immunological assays. 
 
Management: 
                 The most common and conventional treatment approach ofAggressive 
Periodontitisis the mechanical therapyin the form of Scaling and Root planing 
(SRP) which is the process of removing the etiologic agents-dental plaque and 
calculus from the exposed surfaces of  teeth andtheir root surfaces with periodontal 
scalers and periodontal curettes under local anaesthesia. In patients with severe 
defects, surgical therapy with graft placement is indicated. 
                Since the major periodontal pathogens may escape from the mechanical 
therapy, this conventional periodontal therapy (SRP) needs to be combined with 
systemic antibiotics.  
               Among all the antibiotics, doxycycline has been found to be the most 
efficacious in the treatment of aggressive periodontitis17.  
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Dosage forms: 
 Available as tablet, capsule, syrup and injectable powder forms. 
 Oral dose is 200 mg initially, then 100-200mg once daily. 
Common indications: 
 Venereal diseases 
  Atypical pneumonia 
  Cholera  
 Brucellosis  
 Plague 
  Relapsing fever 
 Rickettsial infections 
 Anthrax 
 Leptospirosis 
 Acne vulgaris 
 Periodontitis 
Adverse effects: 
 Epigastric pain, nausea, vomiting and diarrhea 
 Phototoxicity 
Drug interactions: 
 Enzyme inducers such as phenytoin, carbamazepine – reduce its serum level 
 It can increase the action of warfarin by inhibiting the production of  
vitamin K in intestines. 
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Role of Doxycycline in Periodontitis:20 
 The growth of the main organism is inhibited by Doxycycline aided by its 
tendency to concentrate in periodontal region.  
 
 Additional features of anti-collagenase effect and it's regenerating capacity in 
bone plays a part in the cure. 
 
 
Why new drug is needed? 
                  Mechanical removal of plaque and calculus may not eliminate the 
periodontal pathogens completely from the root surfaces of teeth which necessitates 
the adjunctive therapy of systemic antibiotics. But, the misuse, overuse of 
antibiotics have led to drug resistance.21 
                  Hence, time has come for the application of health-promoting bacteria 
(Synbiotics) in the management of aggressive periodontitis. They act mainly by 
preventing the growth of pathogenic bacteria and promoting the beneficial bacteria, 
thereby improving the periodontal health.22 
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SYNBIOTICS 
Synbiotics are synergistic combination of probiotics and prebiotics. They 
impede the disease progression, modify plaque, alter the colonization of anaerobic 
bacteria, heal formed pockets and reduce loss of clinical attachment. 
 
Prebiotics 
Prebiotics are non-digestible food components that stimulate probiotics. 
Recently, the definition has been refined to include selectively fermented 
ingredients that allow specific changes, both in the composition and/or activity in 
the gastrointestinal microflora that confer benefits upon host well-being and 
health.23 
 
Sources of prebiotics:24 
 Soybeans 
 Inulin sources  
         -Jerusalem artichoke    
         - Jicama  
         -Chicory root 
 Raw oats 
 Unrefined wheat 
 Unrefined barley 
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 Mutated bacterial species of Clostridim butyricum, Streptococcus fecalis, 
Bacillus mesentricus 
Commonly used prebiotics:25,26 
1. Oligofructose  
2. Inulin 
3. Galacto oligosaccharides  
4. Lactulose 
Prebiotics with increased function have also been designed. They are derivatives of 
oligosaccharide which acts as receptors of epithelial cells. The pathogensits on these 
receptors rather than epithelial cells and thereby hinder their action. 
Short-chain prebiotics: 
 e.g., oligofructose - act on right side of the colon providing nourishment to the 
bacteria in that area. 
Longer chain prebiotics:  
e.g., Inulin – act predominantly in the left side of the colon.  
Full-spectrum prebiotics:  
e.g., oligofructose-enriched inulin (OEI) - act throughout the colon. 
These full-spectrum prebiotics are commonly used in periodontal healthcare. 
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MECHANISM OF ACTION OF PREBIOTICS:27,28 
 Helps in the growth of beneficial microflora 
 Cytokines like IL-10 and interferon γ are produced in larger quantities 
 Secretion of IgA is enhanced 
 Immune response to the infective organism is modified. 
 The barrier in the gut mucosa is modified. 
 
Probiotics: 
           Live microorganisms that are provided to our body to produce beneficial 
effects are called as probiotics. The concept of probiotics was first introduced by 
Elie Metchnikoff, a Russian scientist, following his observation that Bulgarian 
people had a longer life span due to the consumption of fermented milk containing 
viable bacteria.  
                   The term “Probiotic” was initially proposed by Lilley and Stillwell in 
1965. The word “Probiotics” was originally derived from a composite of the Latin 
preposition pro ("for") and the Greek noun bios ("life")29. First probiotic species to 
be introduced in research was Lactobacillus acidophilus by Hull et al in 1984 
followed by Bifidobacteriumbifidumby Holcombh et al in 199130.Probiotics 
organisms have been classified by FDA as Generally Regarded as Safe (GRAS). 
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Common sources of probiotics:31 
 Kombucha - a fermented tea  
 Kefir  
 Ginger Beer 
  Moroccan preserved lemons 
  Sour pickles  
 Dairy products 
 
Criteria of an ideal microorganism to be used as probiotics:32,33,34 
 Should be of human origin 
 Should be non pathogenic 
 High cell viability, resistant to low pH and acids 
 Persisting nature 
 Capacity to adhere 
 Signal sending capacity to cells involved in immune response.  
 Resistance to processing 
 Ability to regulate local metabolism. 
 
Essential requisites for microorganisms to exert probiotic properties in the oral 
cavity: 
 To adhere to the saliva coated surfaces 
 To colonize and grow in the mouth 
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 To inhibit oral pathogens 
  To resist the oral environmental conditions and defense mechanisms 
 To be also safe for the host. 
 
The mechanisms by which beneficial bacteria act are:35 
o By passively occupying a niche that may be otherwise colonized by 
pathogens  
o Actively limiting the pathogens ability to adhere to appropriate surfaces  
o By adversely affecting the growth or vitality of the pathogen  
o By affecting the ability of the pathogen to produce virulence factors  
o By degrading the virulence factors produced by the pathogen 
o  By providing bioactive or regulatory peptides  
o Through modifying immune system, altering permeability of epithelial cells 
and translocation. 
 
Mechanisms of action of Probiotics in periodontal diseases:  
 Inhibition of specific organisms  
 Invasion by microorganism and formation of biofilm are inhibited. 
 By producing substances like hydrogen peroxide and bacteriocins 
that kill the microorganisms. 
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 Effects on host response  
 Inhibition of collagenases and reduction of inflammation associated 
molecules 
 Induction of expression of cytoprotective proteins on host cell 
surfaces 
 Prevention of cytokine-induced apoptosis 
 Modulation of pro-inflammatory pathways induced by pathogens 
 Modifying the response of immune system of host. 
 
IMPORTANT STRAINS IN PROBIOTIC FORMULATIONS:36 
1. Lactobacillus.  
2. Streptococcus 
3. Bacillus species 
4. Clostridium  
5. Bifidobacteria  
6. Streptomyces  
7. Yeasts and moulds like Saccharomyces boulardii  
 
Lactobacillus species: 
     They are gram positive, lactic acid producing bacteria. They are found 
mainly in the small intestine. Lactobacillus sporogenes is non pathogenic bacterium 
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naturally occurring in intestine. It is responsible for synthesis of vitamin B complex 
and also responsible for synthesis of digestive enzymes. These spores proliferate in 
the small intestine and produce lactic acid which inhibits the enteric pathogenic 
organisms. 
Lactobacillus rhamnosus improves body immunity and prevents antibiotic 
associated diarrhoea. Lactobacillus reuteri is used in prevention of H.pylori and 
gingival infection. Lactobacillus acidophilus and Lactobacillus plantarum are also 
used as probiotic supplements.  
                Oral administration of tablets containing L.salivariussignificantly lowered 
the numbers of periodontal pathogenic bacteria in plaque and improved periodontal 
health in two double blinded, placebo controlled, randomized clinical trials 
(Shimauchi et al, 2008 and Mayanagi et al, 2009)37,38. 
               Lactobacillus reuteriimproved the gingival bleeding index and reduced 
bacterial plaque (Krasse et al, 2006)39 and caused a decline in gingival bleeding and 
inflammatory mediators (Twetman et al,2009)40. The use of probiotic lozenges 
containing Lactobacillus brevis was recently reported to significantly improve the 
periodontal health of subjects with aggressive periodontitis (Shah et al. 2013). 
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Bifidobacterium species: 
    Bifidobacteria are gram positive, micro aerophillic that are highly 
prevalent in human intestines. Bifidobacterium animalis and Bifidobacterium 
longum are used in infantile diarrhea. 
               In a double-blinded, randomized crossover trial, Caglar et alfound that 
salivary S.mutanscounts significantly declined after consumption of ice-cream 
containing Bifido bacterium lactis (Caglar et al, 2008).41 
                Lee et al. reported that Bifidobacterium adolescentisand Bifidobacterium 
longum inhibited both Streptococcus mutansand Streptococcus sobrinus, both 
reported as being cariogenic (Lee et al, 2011).42 
 
Streptococcus faecalis: 
     They are gram positive, aerobic, non spore forming cocci that proliferate 
with bacillus mesentricusand clostridium butyricum to produce lactic acid which 
inhibit harmful bacteria including periodontal pathogens. 
Clostridium butyricum: 
     They are live gram positive spore forming bacilli producing butyric acid 
and acetic acid which decrease intestinal pH and prevents growth of harmful 
bacteria. 
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Bacillus species: 
 Bacillus mesentricus and spores of Bacillus clausii have probiotic action. 
Live gram positive spore forming bacilli that produces an amylolytic enzyme and 
protease to activate proliferation of streptococcus43. 
 
USES OF PROBIOTICS:  
 
GASTROINTESTINAL TRACT: 
    Probiotics containing β galactosidase helps in improving lactose 
intolerance. Intake of probiotics like Saccharomyces cerevisiae helps in degradation 
of sucrose in children with sucrase deficiency. Deficiency of beneficial 
microorganisms and overgrowth of clostridium difficle are responsible for the 
occurrence of Antibiotic associated diarrhea(Hawrelak et al 2005).44 Use of 
Saccharomyces boulardii has been shown to improve the condition by replacing the 
beneficial micro flora. 
   Probiotics are also being used in prevention and treatment of Rotavirus 
associated diarrhoea. The effects are due to production of acids, hydrogen peroxide, 
antimicrobial substances, competition for nutrients or adhesion receptors, antitoxin 
actions and stimulation of immune system. Probiotics have also been found to be 
effective in antibiotic associated diarrhoea. Lactobacillus reduces the risk of 
colorectal cancer by reducing the activity of certain fecal enzymes which convert 
the procarcinogens to carcinogens (Ouwehand et al. 2002)45. 
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Eradication of Helicobacter pylori  
               Several lactobacilli and bifidobacterial strains as well as Bacillus 
clausiiappear to reduce the side effects of antibiotic therapies and improve patient 
compliance. Several strains were effective in decreasing side effects and increasing 
the eradication rates (Gaon et al2002)46. 
Hepatic encephalopathy  
    It is a complication of liver cirrhosis that can be prevented and treated by 
lactulose which is a prebiotic.  
Irritable bowel syndrome (IBS)  
            Compared to placebo,probiotics  are found  to have  beneficial effects. 
Studies have shown that it reduces bloating and flatulence of abdomen. Several 
studies have demonstrated significant therapeutic gains with probiotics in 
comparison with placebo.  Some strains may ameliorate pain and provide global 
relief (B. infantis35624) in addition. Lactobacillus reuteri   improves colicky 
symptoms within one week. 
 
HALITOSIS: 
   Probiotics such as Streptococcus salivarius produces bacteriocins which 
inhibit bacteria producing Volatile sulphur compounds (VSC) that are responsible 
for halitosis and hence used in the treatment and prevention of halitosis47. 
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DENTAL CARIES:  
               Probiotics prevent the cariogenic bacteria from adhering and therefore 
reduce their chances of producing acidic byproducts that are responsible for the 
development of dental caries.48 
 
PERIODONTAL DISEASES: 
               By preventing the colonization of periodonto pathogens, probiotics exhibit 
lower probing depths and less loss of clinical attachment and improve both clinical 
and microbiologic parameters in gingivitis and periodontitis patients.  
 
ATOPIC DISEASE:  
   Lactobacilli reduce the gut permeability, increases gut specific IgA 
response, promotes the barrier function of the intestines by restoring beneficial 
microbes to normal level. They also enhance the production of TGF-β and IL-10 
and increase the level of cytokines that promote the production of IgE antibodies.49 
 
UROGENITAL INFECTIONS: 
    L.rhamnosus and L.reuteri strains when applied topically helps in 
prevention of urogenital infections.50 
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ENT INFECTIONS 
 α-Hemolytic Streptococci have an interfering activity against pathogens that 
cause otitis media.50 
 
APHTHOUS ULCER 
      Probiotics are beneficial in treatment of recurrent aphthous ulcers of the 
mouth. The ability of lactobacillus to increase the activity of phagocytes must be the 
key factor in combating recurrent aphthous ulcer50. 
 
EFFECT ON CANDIDIAL INFECTIONS 
      Probiotics reduce the prevalence of oral candidiasis and risk of hypo 
salivation in elderly.51 
 
Suitable formulation of Probiotics for periodontal disease management: 
                Lozenges, Chewing gums, Tooth pastes and Mouth rinse - these things 
facilitate enough contact with oral cavity and also help in the adhesion of 
probiotics.52,53 
 
Adverse effects: 
              Probiotics are generally considered safe and well tolerated with bloating 
and flatulence occurring frequently54. 
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RATIONALE OF USING SYNBIOTICS IN AGGRESSIVE 
PERIODONTITIS: 
 
                    The main pathogenic agents associated with aggressive periodontitis 
areAggregatibacter actinomycetemcomitans, P. gingivalis, Treponema denticolaand 
Tannerella forsythus. These bacteria have a variety of virulent characteristics 
allowing them to colonize the subgingival sites, escape the host’s defense system 
and cause tissue damage. The persistence of the host’s immune response also 
constitutes a determining factor in progression of the disease.  
                   The beneficial effects of probiotics in periodontal diseases have been 
explored in many studies. The common mechanism of action includes inhibition of 
pathogen adhesion, colonization through the production of antimicrobial substances 
and modulation of host immune response. 
                   Many studies have shown that probiotics can reduce the probing depths 
and clinical attachment loss and significantly improve the periodontal health of 
subjects with aggressive periodontitis.  
                   Hence, this approach may provide a valuable addition or alternative to 
the treatment options for periodontitis. 
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OBJECTIVE 
 
OBJECTIVE: 
To evaluate the efficacy and safety of Synbiotic as an Add on therapy to 
Standard treatment in the management of patients with Aggressive Periodontitis 
compared to Standard treatment alone. 
 
PRIMARY END POINT: 
 
 Reduction in Probing depth & Clinical attachment loss 
 
SECONDARY END POINT: 
 
 Reduction in Oral hygiene index & Gingival bleeding index 
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METHODOLOGY 
The study was conducted in patients diagnosed with Aggressive Periodontitis 
and attending outpatient department of Periodontics, GovernmentDental College, 
Chennai. 
Study design: 
 A Randomized, Prospective, Placebo controlled, Interventional study. 
Study population: 
  Patients (18-30yrs old) with Aggressive Periodontitis (localized & 
generalized) attending outpatient department of Periodontics 
Study center: 
        Institute of Pharmacology, Madras Medical College in collaboration with  
Department of Periodontics, Government Dental College, Chennai. 
Study period: 
        August 2014 to April 2015. 
Study duration: 
Treatment period of 8 weeks and Post treatment follow up period of 4 weeks 
per patient. 
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Sample size: 
60 patients (Control group - 30,Study group - 30). 
Inclusion criteria: 
 Age: 18-30 years  
 Sex-both genders 
 Patients recently diagnosed with Aggressive Periodontitis 
 Patients willing to give written informed consent and come for follow up 
 Patients adhering to oral hygiene instructions and education. 
Exclusion criteria: 
 Smokers and Alcoholics 
 Pregnant and lactating women 
 Patients treated with pre / probiotics in the last one month 
 Patients allergic to prebiotics/probiotics 
 Participation in another clinical study in the last three months 
 Patients with Diabetes,Hypertension, chronic systemic illness of liver, heart, 
Kidney and HIV infection/AIDS. 
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Study procedure: 
 The study was conducted after obtaining the approval from Institutional 
Ethics Committee, Madras Medical College and it was done in accordance with 
declaration of Helsinki and Good Clinical practice (GCP) guidelines.  
 Patients diagnosed with Aggressive Periodontitis attending the Outpatient 
department of Periodontics, Government Dental College and Hospital were 
explained about the study purpose, procedure and benefits of the study.   
            After obtaining writteninformed consent in patient's own language, the study 
was carried out. The demographic details of the patients were recorded.The subjects 
were screened by complete medical and dental history, clinical and oral 
examination and laboratory investigations. Those who fulfilled all the inclusion and 
exclusion criteria were enrolled in the study. 
Randomization: 
          The enrolled patients were randomized by simple randomization into either 
control group or study group and received the respective therapy. Patients were 
blinded to the groups they were assigned to. 
 Control group (n=30) –Standard therapy + Placebo 
 Study group (n=30) – Standard therapy + Synbiotic  
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TREATMENT PLAN: 
Standard treatment: 
 Scaling and Root Planing (SRP)  
 Cap. Doxycycline  100 mg  twice (1-0-1) daily for one week 
Control group: 
Standard treatment 
+ 
Placebo – one lozenge twice (1-0-1) daily for 8 weeks 
(Lactose containing lozenge-identical in colour, size and shape to the study 
drug) 
Study group: 
Standard treatment 
 
           +  
 
Synbiotic–one lozenge twice (1-0-1)daily for 8 weeks. 
Composition of synbiotic: 
Each lozenge contains 
 Streptococcus faecalis  T-110   JPC      -   30 million 
 Clostridium butyricum TO-A    IHS     -   2 million 
 Bacillus mesentricus TO-A       JPC     -   1 million 
 Lactobacillus sporogenes        IHS       -   50 million. 
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Patients were instructed to place the lozenges in the oral cavity for a few minutes, 
allowing them to dissolve to increase the contact time in the mouth where it acts 
locally.  
 
 
ASSESSMENT PARAMETERS: 
 Probing depth  
 Clinical attachment loss 
 Oral hygiene index  
 Gingival bleeding index 
 
Standardized tables are used to measure all these parameters. In these tables, two 
digit numbers are used. First digit denotes number of quadrant; second digit denotes 
number of tooth in that particular quadrant. Dentition has been divided into four 
quadrants; each quadrant has eight teeth. 
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Probing Depth (PD) & Clinical Attachment Loss (CAL) (in mm):7,11,55 
PD – distance from the free end of the gingival margin to the bottom of the 
periodontal pocket 
CAL – distance from Cemento Enamel Junction (CEJ) to the bottom of the 
periodontal pocket 
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            This probe whose end is blunt, is thin and long. The main use of this probe 
is to assess the health of the periodontal region by means of measuring the depths of 
the pockets formed around the tooth. This also has markings which can be utilized 
for measuring accurately. 
                  The tip of this instrument is placed with light pressure into the gingival 
sulcus, which is an area of potential space between a tooth and the surrounding 
tissue. It is important to keep the periodontal probe parallel to the contours of the 
root of the tooth and to insert the probe down to the base of the pocket. This results 
in obscuring a section of the periodontal probe's tip. The first marking visible above 
the pocket indicates the measurement of the pocket depth. It has been found that the 
average, healthy pocket depth is around 3 mm with no bleeding upon probing. 
Depths greater than 3 mm can be associated with attachment loss of the tooth to the 
surrounding alveolar bone, which is a characteristic sign found in periodontitis.  
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According to the American Academy of Periodontology, the classification of 
severity is as follows: 
Mild: 1-2mm of attachment loss 
Moderate: 3-4mm of attachment loss 
Severe: ≥5mm of attachment loss 
 
Maxillary:                                              
                                                                  Palatal 
CAL                 
PD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PD                 
CAL                 
                                                      Buccal 
 
Mandibular: 
                                                     Lingual 
CAL                 
PD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PD                 
CAL                 
                                                     Buccal 
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Oral Hygiene Index(OHI):7,11 
 
OHI=Debris Index (DI) + Calculus Index (CI) 
 
Debris or Calculus index=Total score/Number of teeth examined 
 
  Criteria for classifying debris: 
 
Scores Criteria 
0 No debris or stain present 
1 Soft debris covering not more than one third of the tooth 
surface, or presence of extrinsic stains without other debris 
regardless of surface area covered 
 2 Soft debris covering more than one third, but not more than two 
thirds, of the exposed tooth surface. 
3 Soft debris covering more than two thirds of the exposed tooth 
surface. 
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Criteria for classifying calculus: 
 
Scores Criteria 
0 No calculus present 
1 Supragingival calculus covering not more than third of the exposed 
tooth surface. 
2 Supragingival calculus covering more than one third but not more 
than two thirds of the exposed tooth surface or the presence of 
individual flecks of subgingival calculus around the cervical portion 
of the tooth or both. 
3 Supragingival calculus covering more than two third of the exposed 
tooth surface or a continuos heavy band of subgingival calculus 
around the cervical portion of the tooth or both. 
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Debris index-score:         Calculus index-score: 
 
 
 
DI-S=                                                                    CI-S=    
 
INFERENCE: 
0.0 –1.2   = Good oral hygiene   
1.3 – 3.0  = Fair oral hygiene   
3.1 – 6.0  = Poor oral hygiene   
 
 
 
 
 
 
 
 
 
   
16 11 26 
46 31 36 
   
   
16 11 26 
46 31 36 
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Gingival Bleeding Index:7,11,56 
 
Bleeding on probing (BoP), even with a gentle touch can occur in periodontitis. It is 
due to the periodontal probe damaging the increased blood vessels in the capillary 
plexus of the lamina propria, which are close to the tooth surface because of the 
ulceration of the junctional epithelium (JE). The presence of bleeding is one of the 
first clinical signs of active periodontal disease.  
 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
If Bleeding on Probing (BoP)  is present, it is recorded as  + 
If Bleeding on Probing (BoP)  is absent , it is recorded as  -- 
 
 
 
 
 
55 
 
SCREENING: 
 Written informed consent obtained. 
 Demographic details obtained. 
 Medical and Dental history taken and recorded.  
 Vital signs recorded. 
 General, Systemic & local (intra oral) examination done. 
 Laboratory investigations done. 
 X ray - Intra Oral Peri-apical radiograph / Orthopantamogram taken. 
 
VISIT 1 (Baseline): 
 Randomization done. 
 Vital signs recorded. 
 Oral hygiene index &Gingival bleeding index measured. 
 Probing depth & Clinical attachment loss measured. 
 Scaling and Root planing was done. 
 Study drugs were issued for 2 weeks to respective groups. 
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 Instructed to return the empty bottles and strips during subsequent 
visit. 
 Patients were instructed to report if any adverse events occur. 
 
VISIT 2 (end of 2 weeks) 
 Vital signs recorded. 
 Patients were asked to return empty bottles to check compliance. 
 Intra oral examination was done.  
 Adverse events monitored. 
 Study medication issued for subsequent 2 weeks. 
 
VISIT 3 (end of 4 weeks) 
 Vital signs recorded. 
 Patients were asked to return empty bottles to check compliance. 
 Intra oral examination was done.  
 Adverse events monitored. 
 Oral hygiene index &Gingival bleeding index measured. 
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 Probing depth & Clinical attachment lossmeasured. 
 Study medication issued for subsequent 2 weeks. 
 
VISIT 4 (end of 6 weeks) 
 Vital signs recorded. 
 Patients were asked to return empty bottles to check compliance. 
 Intra oral examination was done.  
 Adverse events monitored. 
 Study medication issued for subsequent 2 weeks. 
 
VISIT 5 (end of 8 weeks) 
 Vital signs recorded. 
 Patients were asked to return empty bottles to check compliance. 
 Intra oral examination was done.  
 Adverse events monitored. 
 Oral hygiene index &Gingival bleeding index measured. 
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 Probing depth & Clinical attachment lossmeasured. 
 Laboratory investigations done. 
 
VISIT 6 (end of 12 weeks) 
 Vital signs recorded. 
 Intra oral examination was done.  
 Oral hygiene index &Gingival bleeding indexmeasured. 
 Probing depth & Clinical attachment lossmeasured. 
 
 
Lab investigations: 
The following laboratory investigationswere performed in the patients on 
screening and at the end of 8 weeks. 
 Haematology - Haemoglobin, Total leucocyte count, Differential count. 
 Blood glucose 
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Follow up: 
 The patients were further followed up for a post treatment period of 4 weeks 
for the assessment of aggressive periodontitis. 
            After the completion of 12 weeks of study period, the patients were 
provided appropriate dental care at Department of Periodontics, Government Dental 
College, Chennai. 
 
Adverse events: 
Any adverse event reported by the patient or observed by the dentist during 
the study was recorded. The onset of adverse event, causal relationship to the study 
drug and action taken was recorded. Appropriate medical care was provided. 
 
Withdrawal: 
During the study period the subject was allowed to withdraw his/her 
voluntary consent and opt out of study. Similarly at the discretion of the 
investigator, the subjects were withdrawn from the study if any serious adverse 
event was reported by the patient or observed by the dentist. 
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Statistical analysis: 
The obtained data was analyzed statistically.  
Distribution of age was analyzed using one way ANOVA and Sex 
distribution was analyzed by Pearson chi- square test. 
The biochemical investigations were performed at baseline and at the end of 
8 weeks. The differences within the groups before and after treatment were 
analyzed using student’s paired t- test.  
The difference within the groups in probing depth, clinical attachment loss 
and oral hygiene index score was analyzed using students paired t-test. Similarly the 
difference between the control and test groups was analyzed using independent t-
test. Gingival bleeding index was analyzed by Pearson chi- square test. 
Statistical analysis was done by using SPSS software version 21. 
p value <0.05 was considered to be statistically significant. 
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RESULTS 
 
This study was conducted to evaluate the efficacy and safety of synbiotic as 
add on therapy to Standard treatment in patients with Aggressive Periodontitis 
compared to standard treatment alone. 
106 patients were screened, of which 38 patients were excluded from the 
study based on exclusion criteria and 8 patients who were eligible for the study 
were not willing to participate. 
Thereby 60 patients were enrolled in this study and were randomized into 
either of the 2 groups: Control group [Standard therapy + Placebo] and Study group 
[Standard therapy +Synbiotic]. Each group consisted of 30 patients. All the enrolled 
patients completed the study. 
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STUDY FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCREENED – 106 
ENROLLED - 60 
TREATMENT PERIOD – 8 WEEKS 
CONTROL GROUP 
n = 30 
STUDY GROUP 
 n = 30 
RANDOMIZATION 
60 PATEINTS COMPLETED THE STUDY 
STATISTICAL ANALYSIS 
EXCLUDED – 46  
POST TREATMENT FOLLOW UP PERIOD – 4 WEEKS 
  
 
 
 
 
 
Ta
gro
wa
gro
Fig
gro
ble-1 show
ups. The m
s 23.5.The
ups. 
ure-1 indi
ups 
A
G
E
   
 IN
   
 Y
E
A
R
S 
  
G
CO
p
TAB
s the Mean
ean age o
re was no s
FIGU
cates the M
0
5
10
15
20
25
30
35
CO
ROUP 
NTROL 
STUDY 
-VALUE 
LE-1: ME
 Age Distr
f patients in
tatistically
RE -1 ME
ean Age D
NTROL
23.4
NO. 
PATIEN
30
30
63 
AN AGE D
ibution of 
 control gr
 significant
AN AGE 
 
istribution
ST
OF 
TS (n) 
 
 
ISTRIBU
patients am
oup was 2
 difference
DISTRIBU
 of patients
UDY
23.5
MEAN AG
IN YEAR
23.4 
23.5 
p = 0.907
TION 
ong the co
3.4 and in 
 in mean a
TION 
 among co
C
S
E 
S 
S.D
3.0
3.4
ntrol and s
the study g
ge between
ntrol and s
ONTROL
TUDY
 
5 
9 
tudy 
roup 
 the 
 
tudy 
  
 
 
 
Ta
fem
bet
ble 2 show
ales was 
ween the g
1
1
1
1
1
2
N
O
   
O
F 
  P
AT
IE
N
T
S
 
GR
CON
ST
TA
s the distri
higher than
roups. 
FIG
Figure-
0
2
4
6
8
0
2
4
6
8
0
CON
OUP 
TROL 
UDY 
BLE-2: GE
bution of s
 males. T
URE-2: G
2 is the gra
TROL
13
17
MALE
N 
13 
12 
64 
NDER DI
ex in the co
here was n
ENDER D
phical repr
 
ST
1
 F
% N
43 17
40 18
STRIBUT
ntrol and s
o statistic
ISTRIBUT
esentation 
UDY
2
18
EMALE 
 %
 57
 60
ION 
tudy group
ally signifi
ION 
of table-2 
TOT
  N 
30 
30 
s.Percentag
cant differ
MALE
FEMALE
AL 
% 
100 
100 
e of 
ence 
  
 
 
 
Ta
gro
Th
 
TA
 
 
ble-3 show
ups.Gener
ere was no 
FIG
0
2
4
6
8
10
12
14
16
18
20
GR
CON
ST
p-V
BLE-3: T
s the type
alized aggr
statistically
URE-3: T
Figure-
CONT
10
OUP 
TROL 
UDY 
ALUE 
YPES OF 
s of aggres
essive peri
 significan
YPES OF
3 is the gra
ROL
20
LOCALIZ
10 
9 
65 
AGGRES
sive period
odontitis w
t difference
 AGGRES
 
phical repr
STUD
9
ED GE
p
SIVE PER
ontitis in b
as more co
 between t
SIVE PER
esentation 
Y
21
NERALIZ
20 
21 
 = 0.92 
IODONTI
oth the co
mmon in b
he groups. 
IODONT
of table-3 
LOCAL
GENER
ED TO
3
3
TIS 
ntrol and s
oth the gro
ITIS  
IZED
ALIZED
TAL 
0 
0 
tudy 
ups. 
66 
 
 
TABLE-4:MEAN PROBING DEPTH(in mm): 
 
 CONTROL 
GROUP 
STUDY  GROUP INDEPENDENT 
T-TEST 
MEAN SD MEAN SD 
BASELINE 5.63 0.71 5.60 0.67 p=0.85 
WEEK 4 4.46 0.73 3.66 0.75 P<0.01 
WEEK 8 3.69 0.66 3.13 0.34 P<0.01 
WEEK 12 3.60 0.49 3.10 0.30 P<0.01 
p-VALUE p<0.01 p<0.01  
 
Table-4 shows mean probing depth in both the groups from baseline to week 12. 
 Statistical analysis within the group showed a significant reduction in mean 
probing depth in both the control and study groups. 
 Comparison between the groups showed statistically significant reduction in 
mean probing depth from week 4 onwards. 
 Post treatment follow up period at week 12 showed lesser mean probing 
depth in the study group than the control group. 
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FIGURE-4 MEAN PROBING DEPTH(in mm):  
 
 
 
 
Figure-4 is the graphical representation of table-4. 
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TABLE-4A: MEAN PROBING DEPTH(in mm) 
BASELINE vs 8 WEEKS  
 
 CONTROL 
GROUP 
STUDY 
GROUP 
p-VALUE 
BASELINE 5.63 5.60      =  0.85 
8 WEEKS 3.69 3.13 <0.01 
 
 
Table-4A shows mean probing depth in both the groups at baseline and week 8. 
 There was a statistically significant reduction in mean probing depth in the 
study group at week 8 (p < 0.01). 
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TABLE-5:MEAN CLINICAL ATTACHMENT LOSS(in mm): 
 
 
 CONTROL 
GROUP 
STUDY  GROUP INDEPENDENT 
T-TEST 
MEAN SD MEAN SD 
BASELINE 7.36 0.76 7.46 0.77 p=0.62 
WEEK 4 6.17 0.75 5.53 0.78 P=0.02 
WEEK 8 5.37 0.72 5.00 0.53 P<0.01 
WEEK 12 5.36 0.71 4.96 0.49 P<0.01 
p-VALUE p<0.01 p<0.01  
 
Table-5 shows mean clinical attachment loss in both groups from baseline                      
to week 12. 
 Statistical analysis within the group showed a significant reduction in mean 
clinical attachment loss in both the control and study groups. 
 Comparison between the groups showed statistically significant reduction in 
mean clinical attachment loss from week 4 onwards. 
 Post treatment follow up period at week 12 showed lesser mean clinical 
attachment loss in the study group than the control group. 
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FIGURE-5 MEAN CLINICAL ATTACHMENT LOSS(in mm):  
 
 
 
 
Figure-5 is the graphical representation of table-5. 
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TABLE-5A: MEAN CLINICAL ATTACHMENT LOSS(in mm) 
BASELINE vs 8 WEEKS  
 
 CONTROL 
GROUP 
STUDY 
GROUP 
p-VALUE 
BASELINE 7.36 7.46      =  0.62 
8 WEEKS 5.37 5.00 <0.01 
 
 
Table-5A shows mean clinical attachment loss in both the groups at baseline and  
week 8. 
 There was a statistically significant reduction in mean clinical attachment loss in 
the study group at week 8( p<0.01). 
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TABLE-6: MEAN ORAL HYGIENE INDEX: 
 
 
 CONTROL 
GROUP 
STUDY  GROUP INDEPENDENT 
T-TEST 
MEAN SD MEAN SD 
BASELINE 1.99 0.50 1.96 0.49 p=0.83 
WEEK 4 1.35 0.09 1.25 0.06 P<0.01 
WEEK 8 1.51 0.18 1.38 0.12 P<0.01 
WEEK 12 1.67 0.19 1.51 0.18 P<0.01 
p-VALUE p<0.01 p<0.01  
 
Table-6 shows mean oral hygiene index in both the groups from baseline                     
to week 12. 
 Statistical analysis within the group showed a significant reduction in mean oral 
hygiene index in both the control and study groups. 
 Comparison between the groups showed statistically significant reduction in 
mean oral hygiene index from week 4 onwards. 
 Post treatment follow up period at week 12 showed lesser mean oral hygiene 
index in the study group than the control group. 
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FIGURE-6 MEAN ORAL HYGIENE INDEX:  
 
 
 
 
Figure-6 is the graphical representation of table-6. 
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TABLE-6A: MEAN ORAL HYGIENE INDEX 
BASELINE vs 8 WEEKS  
 
 CONTROL 
GROUP 
STUDY 
GROUP 
p-VALUE 
BASELINE 1.99 1.96      =  0.83 
8 WEEKS 1.51 1.38 <0.01 
 
 
Table-6A shows mean oral hygiene index in both the groups at baseline and                 
week 8. 
 Comparison between the groups showed a statistically significant reduction 
in mean oral hygiene index at week 8 (p <0.01). 
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TABLE-7: MEAN GINGIVAL BLEEDING INDEX: 
 
(BOP – Bleeding on Probing) 
 
 CONTROL GROUP
(NO.OF  
PATIENTS) 
STUDY  GROUP 
(NO.OF  
PATIENTS) 
 
CHI-SQUARE
TEST 
BOP 
POSITIVE 
% BOP 
POSITIVE 
% 
BASELINE 30 100 30 100 p=0.83 
WEEK 4 7 23 1 3 P<0.02 
WEEK 8 6 20 0 0 P<0.01 
WEEK 12 5 17 0 0 P<0.01 
p-VALUE p<0.01 p<0.01  
 
Table-7 shows mean gingival bleeding index in both groups from baseline to                  
week 12. 
 Statistical analysis within the group showed a significant reduction in mean 
gingival bleeding index in both the control and study groups. 
 Comparison between the groups showed statistically significant reduction in 
mean gingival bleeding index from week 4 onwards. 
 None of the patients had bleeding on probing at week 8 in the study group. 
 FIGURE -7
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TABLE-8A : HAEMOGLOBIN LEVEL (g/dl) 
 
 
 
 
GROUPS 
BASELINE 8 WEEKS  
p-
VALUE 
MEAN 
(g/dl) 
MEAN 
(g/dl) 
CONTROL 11.4 11.6 0.22 
STUDY 11.5 11.6 0.18 
 
Table 8A shows the mean haemoglobin level in both groups at baseline and                        
8 weeks. 
 There was no statistically significant difference in the mean haemoglobin 
level in both groups at baseline and 8 weeks. 
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TABLE-8B : TOTAL COUNT (cells/mm3) 
 
 
 
 
 
GROUPS 
BASELINE 8 WEEKS  
p-
VALUE 
MEAN 
(cells/mm3) 
MEAN 
(cells/mm3) 
CONTROL 8564 8463 0.69 
STUDY 8916 8779 0.68 
 
Table 8B shows the mean total count in both groups at baseline and 8 weeks. 
 There was no statistically significant difference in the mean total count in 
both groups at baseline and 8 weeks. 
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TABLE-8C : BLOOD SUGAR(mg/dl) 
 
 
 
 
GROUPS 
BASELINE 8 WEEKS  
p-
VALUE 
MEAN 
(mg/dl) 
MEAN 
(mg/dl) 
CONTROL 95 94 0.80 
STUDY 94 91 0.17 
 
Table 8C shows the mean blood sugar value in both groups at baseline and 
 8 weeks. 
 There was no statistically significant difference in the mean blood sugar 
value in both groups at baseline and 8 weeks. 
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TABLE-9: ADVERSE EVENTS 
 
 
ADVERSE 
EVENTS 
 
CONTROL 
GROUP 
 
STUDY GROUP 
 
NAUSEA 
 
3 
 
2 
 
BLOATING 
 
3 
 
4 
 
ABDOMEN PAIN  
 
3 
 
2 
 
DIARRHOEA 
 
2 
 
1 
 
HEAD ACHE 
 
1 
 
1 
 
 
              Table-9 shows the adverse events noted in both control and study groups.  
 No significant difference was noted in the adverse events between the 
control and study groups. 
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FIGURE – 10: BEFORE TREATMENT 
 
 
 
 
 
Figure 10 shows bleeding on probing and increased probing depth & clinical 
attachment loss. 
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FIGURE – 11: AFTER TREATMENT WITH SYNBIOTIC 
 
 
 
 
Figure 11 shows no bleeding on probing and periodontal probe remains above the 
gingival margin due to decrease in probing depth & clinical attachment loss. 
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DISCUSSION 
              Aggressive periodontitis is characterized by rapid destruction of the 
periodontal ligament and alveolar bone around the affected teeth with increased 
probing depth formation and clinical attachment loss. 
            The standard therapy is Scaling and Root planing with systemic antibiotics. 
These antibiotics can lead to the emergence of drug resistant micro-organisms and 
also disturb the beneficial microflora of the body.  
            Hence, Synbiotics can be added, as they repopulate the beneficial microflora 
and reduce the pathogenic bacteria. The probiotics also produce different 
antimicrobial components which include hydrogen peroxide, organic acids, low-
molecular weight antimicrobial substances and bacteriocins. 
            The use of probiotics was recently reported to significantly improve the 
periodontal health of subjects with aggressive periodontitis, a very destructive form 
of periodontitis (Shah et al. 2013).8 
          This study was done in the Institute of Pharmacology, Madras Medical 
College, Chennai in collaboration with the Department of Periodontics, 
Government Dental College, Chennai.106 patients were screened and 60 patients 
who fulfilled the inclusion criteria were enrolled for the study. They were 
randomized into 2 groups of 30 patients each. 
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          Patients in the control group received the standard treatment in the form of 
Scaling and Root planing with Cap.Doxycycline 100mg twice daily for one week 
and Placebo onelozenge twice daily orallyfor a period of 8 weeks.Patients in the 
study group receivedthe standard treatment andSynbiotic one lozenge twice daily 
orally for a period of 8 weeks. Post treatment follow up was done for a period of 4 
weeks. 
          The efficacy of the treatment was assessed at 4, 8 and 12 weeks by using 
standardized tables for Probing depth[PD],Clinical attachment loss[CAL],Oral 
hygiene index[OHI] and Gingival bleeding index[GBI].  
         Tolerability of the drugs was assessed by laboratory investigations and 
monitoring of adverse events during the study period. The data were collected and 
the results were analyzed statistically. 
        There was no significant difference in the mean age and sex distribution in 
both the control and the study groups. The mean age distribution in both the groups 
was 23. Females were more in numbers than males (17:13 in control group and 
18:12 in study group).Patients with generalized aggressive periodontitis were higher 
in both the groups (20/30 in control group and 21/30 in study group).This correlates 
well with the study conducted by Loe et al5.  
        In this study there was a statistically significant reduction in the probing 
depth(p<0.01) in the study group than the control group at 8 weeks as compared to 
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the findings at baseline. This is in correlation with the studies conducted by 
Shimauchi H et al (2008)37, Vivekananda M et al (2010)57 which also showed a 
statistically significant reduction in the probing depth. 
There was a statistically significant reduction in the Clinical attachment loss 
(p<0.01) in the study group than the control group at 8 weeks as compared to the 
findings on day 0. This correlates well with the studies conducted by Mayanagi et al 
(2009)38, Vivekananda M et al (2010)57 which also showed a statistically significant 
reduction in the Clinical attachment loss. 
         Our study showed a statistically significant decrease (p<0.01) in the  Oral 
hygiene index in the study group than the control group at 8 weeks  as compared to 
the findings on day 0. This was similar to the study done by Krasse P et al (2006)39, 
Kang M et al (2006)58, Riccia D et al (2007)59 which also showed a statistically 
significant reduction in the Oral hygiene index. 
         There was a statistically significant reduction in the Gingival bleeding index 
(p<0.01) in the study group than the control group at 8 weeks as compared to the 
findings on day 0. This is in correlation with the studies conducted by Krasse P et al 
(2006)39, Riccia D et al (2007)59, Tsubura S et al (2009)60, Vivekananda M et al 
(2010)57 which also showed a statistically significant reduction in the Gingival 
bleeding index. 
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         Addition of synbiotics to standard treatment showed a statistically significant 
reduction in mean probing depth, mean clinical attachment loss, mean oral hygiene 
index and Gingival bleeding index when compared to standard treatment alone. 
This correlates well with the studies conducted by Mishal Piyush Shah et al (2013)8. 
        There was no statistically significant difference in the haematological 
parameters like Hemoglobin and Total WBC count and biochemical parameter like 
Blood Sugar in both the control and study groups at the end of treatment period 
when compared with the baseline. This study showed that synbiotic did not have 
any effect in the haematological and biochemical lab parameters.  
No serious adverse events were reported in our study. Abdomen pain, 
Bloating and Nausea were the common adverse events reported during the study 
period in both the groups. Other adverse events noted were diarrhea and headache. 
This suggests that addition of synbiotic is not associated with increase in incidence 
of any adverse events, thereby showing the safety of synbiotic. Similarly the safety 
of synbiotic was also well established in a study done by Chatterjee et al (2011)52. 
Thus synbiotic can be used in patients with aggressive periodontitis and its 
use can improve the periodontal health. Synbiotic was not associated with any 
serious adverse effects and hence can be safely used in the management of 
aggressive periodontitis. 
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CONCLUSION 
 
From this study, we conclude that 
 Synbiotic when added to Standard treatment is more efficacious than 
Standard treatment alone in patients with Aggressive Periodontitis. 
 Synbiotic is well tolerated and is not associated with serious adverse 
events. 
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APPENDIX - I 
LIST OF ABBREVIATIONS USED 
AAP   –  American Academy of Periodontology 
ANOVA –  Analysis of Variance. 
CAL  – Clinical Attachment Loss or Level 
CEJ  –  Cemento Enamel Junction 
CI  –   Calculus Index 
DI  –   Debris Index 
GAP            –  Generalized Aggressive Periodontitis 
GRAS            –  Generally Regarded as Safe 
HLA            –  Human Leukocyte Antigens 
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LAP       –   Localized Aggressive Periodontitis 
LPS  – Lipopolysaccharide 
MHC  – Major Histocompatibility Complex 
OEI            –  Oligofructose-Enriched Inulin 
OHI            –  Oral Hygiene Index  
PD            –  Probing Depth  
PMNs  –  Polymorphonuclear leukocytes 
SRP      – Scaling and Root Planing 
TGF           –   Transforming Growth Factor. 
VSC  –   Volatile Sulphur Compounds 
APPENDIX - II 
ACOMPARATIVE STUDY OF SYNBIOTIC AS AN ADD ON THERAPY TO 
STANDARD TREATMENT IN PATIENTS WITH AGGRESSIVE  
PERIODONTITIS 
 
CASE REPORT FORM 
 
NAME:                               AGE/SEX       :                PLACE: 
 
OP No:                                DIAGNOSIS:   
 
 
Inclusion criteria:        YES/NO 
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 Age: 18-30 years  
 Sex-both genders 
 Patients recently diagnosed with aggressive periodontitis 
 Patients willing to give written informed consent and come for follow up 
 Patients adhering to oral hygiene instructions and education. 
Exclusion criteria:        YES/NO 
 Smokers and Alcoholics 
 Pregnant and lactating women 
 Patients treated with pre / probiotics in the last one month 
 Patients allergic to prebiotics/probiotics 
 Participation in another clinical study in the last three months 
 Patients with Diabetes, Hypertension and chronic systemic illness of liver, 
heart, Kidney, GIT, CNS and HIV infection/AIDS. 
 
Subject initials:       Subject number: 
Subject : Included/Excluded                         Reason if excluded:    
Informed Consent Obtained: Yes/No 
CONTROL/ TEST    
Subject initials:     
Subject number: 
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Signature of principal investigator 
 
VISIT 1 
 
1. Vitals: 
 
2. Medical and Dental History: 
 
3. General /systemic and Local (intra oral) examination: 
4. Investigations: 
 
Hb:                      Total WBC count:   Differential count: 
 
Blood sugar: 
 
X-ray -Intra Oral Peri-apical radiograph / Orthopantamogram 
 
5. Oral hygiene index  
6. Gingival bleeding index 
7. Probing depth  
8. Clinical attachment loss 
 
VISIT 2 
 
1. Vitals: 
 
2. Adverse Events: 
 
VISIT 3 
 
1. Vitals: 
2. Oral hygiene index  
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3. Gingival bleeding index 
4. Probing depth  
5. Clinical attachment loss 
6. Adverse Events: 
VISIT 4 
 
1. Vitals: 
2. Adverse Events: 
VISIT 5 
 
1. Vitals: 
 
2. Oral hygiene index  
3. Gingival bleeding index 
4. Probing depth  
5. Clinical attachment loss 
6. Adverse Events: 
 
7. Investigations: 
 
Hb:                      Total WBC count:               Differential count: 
 
Blood sugar:            
 
 
VISIT 6 
 
1. Vitals: 
 
2. Oral hygiene index  
3. Gingival bleeding index 
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4. Probing depth  
5. Clinical attachment loss 
 
ASSESSMENT 
 
I.Oral Hygiene Index=Debris index+Calculus index: 
Debris index-score:                                    Calculus index-score: 
 
 
DI-S=                                                            CI-S=        
 
II.Gingival Bleeding Index: 
 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
 
 
 
III.ProbingDepth(PD) & Clinical Attachment Loss(CAL) (in mm): 
 
   
16 11 26 
46 31 36 
   
   
16 11 26 
46 31 36 
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Maxillary:                                              
Palatal 
CAL                 
PD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PD                 
CAL                 
Buccal 
 
 
Mandibular: 
Lingual 
CAL                 
PD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PD                 
CAL                 
Buccal 
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APPENDIX - III 
 
PATIENT INFORMATION SHEET 
 
Title:A COMPARATIVE STUDY OF SYNBIOTIC AS AN ADD ON 
THERAPY TO STANDARD TREATMENT IN PATIENTS WITH  
AGGRESSIVE  PERIODONTITIS 
Investigator: 
Name of Participant: 
This study is conducted at the Department of Periodontics, Govt.Dental 
College & Hospital, Chennai. You are invited to take part in this study. The 
information in this document is meant to help you decide whether or not to take part. 
Please feel free to ask if you have any queries or concerns. 
Purpose of this study 
Aggressive Periodontitis causes rapid destruction of tooth-supporting soft 
and hard tissues of the periodontium.Treatment must be pursued with a logical and 
regimented approach.In the recent times when organisms are fast developing 
resistance to antibiotics,the emergence of probiotics appears to be a boon in the 
treatment  of periodontitis along with the conventional periodontal therapy. In this 
study we want to evaluate  the safety and efficacy  of synbiotics as an add on 
therapy to scaling and root planing(SRP).We have obtained permission from the 
Institutional Ethics Committee.  
Study details 
All patients in the study will be randomly allocated to 2 groups- A & B and 
will be given the respective treatment for a period of 8 weeks.  
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Study Procedures 
During this study, blood will be collected from you at the beginning of the 
study. The total amount of blood collected from you will not be more than 7ml. You 
will be asked to come for follow up twice after 8 weeks of completion of study. 
During the course of the study if you notice any adverse events, you have to report 
it. You will be required to return unused study medicines when you report for your 
scheduled visits. This will enable correct assessment of the study results. 
Possible benefits to you – Synbiotics  with your standard medications will provide 
a better clinical outcome particularly in terms of Probing  depth reduction & 
Attachment level gain than SRP alone and will reduce  your future risk of 
developing complications due to Aggressive Periodontitis. 
Possible benefits to other people - The results of the research may provide benefits 
to the society in terms of advancement of medical knowledge and/or therapeutic 
benefit to future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and 
your medical history). By signing this document, you will be allowing the research 
team investigators, other study personnel, sponsors, Institutional Ethics Committee 
and any person or agency required by law like the Drug Controller General of India 
to view your data, if required.The information from this study, if published in 
scientific journals or presented at scientific meetings, will not reveal your identity. 
Participation and Withdrawal from the study 
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Your decision not to participate in this research study will not affect your 
medical care or your relationship with the investigator or the institution. You will be 
taken care of and you will not lose any benefits to which you are entitled. The 
participation in this research is purely voluntary and you have the right to withdraw 
from this study at any time during the course of the study without giving any 
reasons. However, it is advisable that you talk to the research team prior to stopping 
the treatment/discontinuing of procedures etc.The results of this study will be 
informed to you at the end of the study. 
 
Signature of Investigator                                                    Signature of Participant   
 
Date:                                                                                  Date: 
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APPENDIX - V 
 
INFORMED CONSENT FORM 
 
Title: A COMPARATIVE  STUDY OF SYNBIOTIC  AS AN ADD ON 
THERAPY TO STANDARD TREATMENT  IN  PATIENTS  WITH  
AGGRESSIVE  PERIODONTITIS 
Name of the Participant: 
 
I _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been answered. 
I am over 18 years of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in this study. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I am aware of the fact that I can opt out of the study at any time without having to 
give any reasonand this will not affect my future treatment in this hospital.  
6. I hereby give permission to the investigators to release the information obtained 
from me as resultof participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC.Iunderstand that they are publicly presented. 
7. I have understand that my identity will be kept confidential if my data are 
publicly presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signingthis consent form I attest that the information given in this 
document has been clearly explained to meand understood by me, I will be given a 
copy of this consent document. 
 
Name and signature / thumb impression of the participant (or legal representative if 
participantincompetent) 
Name ___________________ Signature_________________ Date_______ 
 
 
Name and Signature of impartial witness (required for illiterate patients): 
Name ______________________ Signature_________________ Date_______ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
Name _____________________ Signature_________________ Date_______ 
